openPR Logo
Press release

Non-Hodgkin Lymphoma Innovative Licensing Industry Opportunities Key Trends, Size, Growth, Shares And Forecast Research Report

03-31-2017 02:41 PM CET | Business, Economy, Finances, Banking & Insurance

Press release from: Non-Hodgkin Lymphoma

Non-Hodgkin Lymphoma Innovative Licensing Industry

Researchmoz added Most up-to-date research on "Frontier Pharma: Innovative Licensing Opportunities in Non-Hodgkin Lymphoma" to its huge collection of research reports.

Non-Hodgkin Lymphoma (NHL) can be seen as a collection of up to 60 smaller subtypes of malignant lymphoid disease, defined by distinct morphological, cytogenetic and immunophenotypic characteristics that can be broadly classified as either indolent or aggressive disease. The slow growing nature of the former means that first-line treatment for diagnosed patients can be delayed, an option not commonly recommended for aggressive disease. Across both indolent and aggressive disease, first-line chemotherapy in combination with the blockbuster drug rituxumab can induce high rates of response, and prolonged durations of remission. Despite this, indolent disease is typically incurable, with the most aggressive lymphoma subtype - diffuse large B-cell lymphoma having 5-year survival rates of ~50%. Re-treatment with chemotherapy can induce second and subsequent remissions, but most NHL patients develop chemotherapy resistant disease, for whom there are limited treatment options. Overall, in terms of numbers small molecule chemotherapeutic agents dominate the current market, with a clear need for novel targeted therapies to prolong durations of remission, and provide options for patients with chemo resistant, heavily pretreated disease.

To Get Sample Copy of Report visit @ http://www.researchmoz.us/enquiry.php?type=S&repid=373016

The current developmental pipeline addresses these gaps in the market, dominated by cancer immunotherapies and inhibitors of cancer-associated signal transduction. Pathways of significant interest include B-cell receptor signaling, the PI3K/Akt/mTOR pathway, and Wnt/ß-catenin signaling, as well as oncogenes such as BCL-6 and BCL-2. Characteristic cell surface molecules that represent targets for cancer immunotherapies include CD19, LMP-1/2 and CD20, with several pipeline drugs already approved for CD20. First-in-class drug development in NHL corresponds strongly to these known somatic mutations and affected pathways. Clinical results of drugs against profiled targets in this report show many are being investigated in relapsed disease.

Scope

There are 666 marketed products for NHL, 95% of which are small molecules -

- What are the dominant mechanisms of action across marketed products?

The treatment of lymphoma is dominated by the use of combination cyclophosphamide based chemotherapy in combination with rituximab -

- What are these chemotherapy regimens?
- How did they perform in key clinical trials?

The variation in molecule type has shifted away from small molecules, whose dominance has decreased to 46% across the pipeline -

- What are the dynamics of the remaining 54% of the pipeline?
- How does this reflect the need for novel targeted therapies?

There is a significant shift away from cytotoxic agents, with the current pipeline dominated by cancer immunotherapies and signal transduction inhibitors -

- What is the scientific rationale behind these mechanisms of action?
- How successful have approved targeted therapies been?

Profiled first-in-class therapies include: PIK3CA, EZH2, CD40 and MDM2 -

- What is the scientific rationale behind these targets?
- What preclinical and clinical results are available for drugs against these targets?
- What is the overall opinion on these targets for drug development across NHL?

Reasons to buy

This report will allow you to -

- Understand the current clinical and commercial landscape. This includes a comprehensive study of disease pathogenesis, diagnosis, prognosis and the available treatment options available at each stage of diagnosis.
- Visualize the composition of the NHL market in terms of dominant molecule types and targets, highlighting what the current unmet needs are and how they can be addressed. This knowledge allows a competitive understanding of gaps in the current market.
- Analyze the NHL pipeline, and stratify by stage of development, molecule type and molecular target. There are promising signs in focussed on the development of targeted therapies for this disease.
- Visualize the clinical safety and efficacy of drugs against first-in-class targets via a detailed heat map, outlining the results across major clinical trial endpoints.
- Identify commercial opportunities in the NHL deals landscape by analyzing trends in licensing and co-development deals, and those first-in-class drugs which are yet to be involved in a strategic alliance.

Make an Enquiry of this report @ http://www.researchmoz.us/enquiry.php?type=E&repid=373016

About ResearchMoz

ResearchMoz is the one stop online destination to find and buy market research reports & Industry Analysis. We fulfill all your research needs spanning across industry verticals with our huge collection of market research reports. We provide our services to all sizes of organizations and across all industry verticals and markets. Our Research Coordinators have in-depth knowledge of reports as well as publishers and will assist you in making an informed decision by giving you unbiased and deep insights on which reports will satisfy your needs at the best price.

Mr. Nachiket
State Tower,
90 State Street,
Suite 700,
Albany NY - 12207
United States
Email: sales@researchmoz.us
Website @ http://www.researchmoz.us/
Tel: 866-997-4948 (Us-Canada Toll Free)
Tel: +1-518-621-2074
Follow us on LinkedIn @ http://bit.ly/1TBmnVG

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Non-Hodgkin Lymphoma Innovative Licensing Industry Opportunities Key Trends, Size, Growth, Shares And Forecast Research Report here

News-ID: 488466 • Views: 180

More Releases from Non-Hodgkin Lymphoma

Heat Map and Analysis on Non-Hodgkin Lymphoma | Industry Analysis & Outlook
Researchmoz added latest report "Non-Hodgkin Lymphoma - Heat Map and Analysis". The industry report lists the leading competitors and provides the insights strategic industry Analysis of the key factors influencing the market. Non-Hodgkin lymphomas (NHL) are a heterogeneous group of malignancies that originate from lymphoid tissue, with varied clinical and biological features. There were an estimated 385,741 new cases of NHL and 199,630 deaths from NHL worldwide in 2012. NHLs are
Non-Hodgkin Lymphoma Market - Pipeline Review, H1 2017 provides Comprehensive In …
ResearchMoz added Latest Research Report titled " Non-Hodgkin Lymphoma - Pipeline Review, H1 2017 " to it's Large Report database. Non-Hodgkin Lymphoma - Pipeline Review, H1 2017 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Non-Hodgkin Lymphoma - Pipeline Review, H1 2017, provides an overview of the Non-Hodgkin Lymphoma (Oncology) pipeline landscape. Non-Hodgkin lymphoma (also known as non-Hodgkin lymphoma, NHL, or sometimes just lymphoma) is a cancer that starts in cells
Latest Research Report on Non-Hodgkin Lymphoma - Heat Map and Analysis | Researc …
Researchmoz added Most up-to-date research on "Non-Hodgkin Lymphoma - Heat Map and Analysis" to its huge collection of research reports. Non-Hodgkin lymphomas (NHL) are a heterogeneous group of malignancies that originate from lymphoid tissue, with varied clinical and biological features. There were an estimated 385,741 new cases of NHL and 199,630 deaths from NHL worldwide in 2012. NHLs are classified as either indolent (slow-growing) or aggressive (fast-growing). Almost 85% of NHLs
Non-Hodgkin Lymphoma - Heat Map and Analysis Industry Key Trends, Size, Growth, …
Researchmoz added Most up-to-date research on "Non-Hodgkin Lymphoma - Heat Map and Analysis" to its huge collection of research reports. Non-Hodgkin lymphomas (NHL) are a heterogeneous group of malignancies that originate from lymphoid tissue, with varied clinical and biological features. There were an estimated 385,741 new cases of NHL and 199,630 deaths from NHL worldwide in 2012. NHLs are classified as either indolent (slow-growing) or aggressive (fast-growing). Almost 85% of NHLs

All 5 Releases


More Releases for NHL

Natural Hydraulic Lime (NHL) Market Size, Share, Development by 2025
LP INFORMATION recently released a research report on the Natural Hydraulic Lime (NHL) market analysis and elaborate the industry coverage, current market competitive status, and market outlook and forecast by 2025. Moreover, it categorizes the global Natural Hydraulic Lime (NHL)market by key players, product type, applications and regions,etc. The main objective of this market research is to help the readers understand the structure of Natural Hydraulic Lime (NHL)market, market definition,
Non Hodgkins Lymphoma (NHL) Therapeutics Market Share and Growth Factors Impact …
Lymphoma is one of the most hazardous and life threatening type of cancer, related to lymphocytes, an important type of white blood cells. Non-Hodgkin’s lymphomas (NHL) is a distinct group of blood cancer, which includes large variety of lymphomas, excluding Hodgkin’s lymphomas. Non-Hodgkin’s lymphoma (NHL) varies in their severity, from mild to fatal. According to a new classification of lymphomas published by WHO in 2008, the lymphomas are segmented into
Non-Hodgkin Lymphoma (NHL) Market Will Hit At CAGR of 8% Between 2012-2023.
Latest industry research report on: Non-Hodgkin Lymphoma Market | Industry Size, Share, Research, Reviews, Analysis, Strategies, Demand, Growth, Segmentation, Parameters, Forecasts DelveInsights Non-Hodgkin Lymphoma (NHL) - Market Insights, Epidemiology and Market Forecast-2023-7MM Reports provides an overview of the disease and global market size of the Non-Hodgkin Lymphoma for the United States, EU5 (France, Germany, Italy, Spain, UK) and Japan. It also includes historical and forecasted epidemiological data for the diagnosed cases
Global Off-highway Dump Truck Market 2017 : Bell, Liebherr, Freightliner, NHL, B …
Global Off-highway Dump Truck market competition by top manufacturers, with production, price, revenue (value) and market share for each manufacturer; the top players including Caterpillar Terex Komatsu Hitachi Construction Machinery John Deere Doosan Belaz Volvo Hydrema The survey report by Market Research Store is an overview of the global Off-highway Dump Truck market. It covers all the recent trends including key developments in the global market in present and in future. Analyses of the global Off-highway Dump Truck market trends
OpportunityAnalyzer: B-Cell Non-Hodgkin’s Lymphoma (NHL) – Opportunity Analy …
ReportBazzar has announced a new report titled “OpportunityAnalyzer: B-Cell Non-Hodgkin’s Lymphoma (NHL) – Opportunity Analysis And Forecasts To 2024” to their offerings. Browse report summery with TOC: http://www.reportbazzar.com/product/opportunityanalyzer-b-cell-non-hodgkins-lymphoma-nhl-opportunity-analysis-and-forecasts-to-2024/ Non-Hodgkin’s lymphoma (NHL) comprises a heterogeneous group of lymphoproliferative malignancies that arise in the B cells, T cells, or natural killer (NK) cells within the lymphoid tissue, such as the lymph nodes, bone marrow, thymus, and spleen. NHLs are further categorized into indolent or aggressive
OpportunityAnalyzer: B-Cell Non-Hodgkins Lymphoma (NHL) - Opportunity Analysis a …
Researchmoz added Most up-to-date research on "OpportunityAnalyzer: B-Cell Non-Hodgkins Lymphoma (NHL) - Opportunity Analysis and Forecasts to 2024" to its huge collection of research reports. Non-Hodgkins lymphoma (NHL) comprises a heterogeneous group of lymphoproliferative malignancies that arise in the B cells, T cells, or natural killer (NK) cells within the lymphoid tissue, such as the lymph nodes, bone marrow, thymus, and spleen. NHLs are further categorized into indolent or aggressive prognostic